bluebird bio (BLUE) Late-Breaker ASH Abstract Provides Proof-Of-Concept - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Wedbush Affirms bluebird bio (BLUE) at 'Outperform'; Late-Breaking ASH Data Bodes Will for bb2121
November 16, 2015 12:40 PM ESTWedbush affirms bluebird bio (Nasdaq: BLUE) with an Pit[erfpr, ratomg amd $165 price target after the company reported Phase 1 results in a late-breaking abstract from a NCI-sponsored study of anti-BCMA CAR-T cells dosed in multiple myeloma patients.
Analyst David M. Nierengarten noted, At lower doses (0.3-1 x 106 cells), 1 patient demonstrated a partial response (PR)... More
